Digitisation | August 10, 2021
Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Deal for 100 million doses with additional 100 million through 2023
Subscribe To Our Newsletter & Stay Updated
